Filing Flows › BioNexus Gene Lab (BGLC) › Q1 2026 › vs Q4 2025
BioNexus Gene Lab (BGLC) Q1 2026 vs Q4 2025 (quarter over quarter)
BioNexus Gene Lab's revenue fell $461K (-95%) from $484K in Q4 2025 to $23K in Q1 2026.
BioNexus Gene Lab, Q1 2026: revenue $23K (-99% year over year), net loss $544K, operating cash flow −$148K. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $23K | $484K | −$461K | -95% |
| Net loss | $544K | $1.0M | −$493K | -48% |
| Costs & expenses | $566K | $1.5M | −$953K | -63% |
| Operating costs | $563K | $1.5M | −$953K | -63% |
| Interest & other, net | $3K | $3K | −$187 | -6% |
| Cost of revenue | $24K | $488K | −$464K | -95% |
| Research & development | $14K | $11K | $3K | +31% |
| Sales & marketing | $53K | $36K | $17K | +48% |
| General & admin | $328K | $181K | $147K | +81% |
| Other operating costs | $145K | $801K | −$656K | -82% |
| Operating cash sources | $544K | $241K | $302K | +125% |
| Depreciation | $28K | $28K | −$137 | -0.5% |
| Working capital & other | $368K | $1.2M | −$806K | -69% |
| Cash used in operations | $148K | −$961K | $1.1M | — |
| Net loss absorbed | $544K | $1.0M | −$493K | -48% |
Questions
How much did BioNexus Gene Lab's revenue grow quarter over quarter in Q1 2026?
BioNexus Gene Lab's revenue fell $461K (-95%) from $484K in Q4 2025 to $23K in Q1 2026.